AbD Serotec Expands Range of HuCAL Antibodies

Mar 15, 2012

AbD Serotec Expands Range of HuCAL Antibodies Used in Clinical Diagnostic Kits 

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that a HuCAL antibody generated by its division for research and diagnostic antibodies, AbD Serotec, has been included in a clinical diagnostic test in the area of maternal health screening by a major diagnostic supplier. The product is CE marked and available within the EU and non-regulated countries. AbD Serotec receives royalties on product sales and will continuously supply the customer with recombinant antibody material.

“Today’s news further increases the number of clinical diagnostic kits relying on a HuCAL antibody as an essential component,” commented Dieter Feger, Head of AbD Serotec. “The market entry of yet another test system including a HuCAL antibody is a further significant step forward for our recombinant technology in the field of in vitro diagnostics. AbD Serotec is committed to continue driving this process as we believe the HuCAL technology enables the generation of superior diagnostics reagents.”

About MorphoSys:

MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare. The company’s AbD Serotec unit uses HuCAL and other antibody technologies to generate superior monoclonal antibodies for research and diagnostic applications.
Together with its pharmaceutical partners, MorphoSys has built a therapeutic pipeline of more than 70 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer’s disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit www.morphosys.com

HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT® and arYla® are registered trademarks of MorphoSys. Ylanthia® and 100 billion high potentialsTM are trademarks of MorphoSys AG.

Slonomics® is a registered trademark of Sloning BioTechnology GmbH, a subsidiary of MorphoSys AG.

This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.

For more information, please contact:

MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122

Mario Brkulj
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454

Jessica Kulpi
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332



Indiana University Medical SchoolIndianapolis, INJuly 23
Washington UniversitySaint Louis, MOAugust 6